Lodenafil carbonate

NEW YORK , June 22, 2022 /PRNewswire/ -- As per Zion Market Research study, The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028. Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports: As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028). Through the primary research, it was established that the Erectile Dysfunction Drugs Market was valued approximately USD 3.64 Billion in 2021 and is projected to reach to roughly USD 5.94 Billion by 2028. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. Zion Market Research published the latest report titled as "Erectile Dysfunction Drugs Market By Therapeutics (Existing Drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline Drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, And Melanocortin Activators), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028." into their research database. Erectile Dysfunction Drugs Market : Overview Erectile dysfunction is the incapability to attain and maintain a hard erection for sexual activity. Having problems with erection isn't usually a reason for fear. However, if erectile dysfunction is a long-term condition, it can create stress, lower self-esteem, and lead to marital issues. Problems obtaining or maintaining an erection can be a symptom of a more serious underlying health issue, as well as a possible risk for cardiovascular disease. To treat such conditions several drugs are available on the market that can help to maintain the erection during sexual intercourse. With a change in lifestyle and increased stress conditions need for these drugs is on the rise. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 190 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Erectile Dysfunction Drugs Market : Growth Drivers Growth in embracing poor lifestyle choices may boost the market growth over the forecast period. With the surge in the adoption of a bad lifestyle, diabetes, obesity, and cardiovascular disease are on the rise, which in turn leads to problems like ED as people become older. The present lifestyle of youth in many emerging countries is very stressful resulting in increased alcoholism, smoking, and fast food or ready-to-eat food consumption. Due to these factors, overall health and fitness are getting compromised which in turn increases the chances of ED. Furthermore, as the senior population grows, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the projection period. Erectile Dysfunction Drugs Market : Restraints Low awareness and side effects associated with erectile dysfunction drugs may hinder the market growth. Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. This is mainly due to less knowledge about these types of medication, low buying power, and less willingness to adopt such kinds of medications in lifestyle. Furthermore, side effects associated with these drugs such as headache, upset stomach, flushing, nasal congestion, vision problems, dizziness, diarrhea, and rash also contribute to the slow growth of the market. Directly Purchase a Copy of the Report @ Global Erectile Dysfunction Drugs Market : Opportunities Increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for market expansion. In the last couple of years, major and emerging brands in pharmaceutical industries have increased their investments in emerging countries like India, China, Africa, and major Middle East countries. This has significantly lowered the cost of medicine along with the supply and the distribution of drugs within the countries which is expected to offer significance. Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market. Global Erectile Dysfunction Drugs Market : Challenges An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge to the market expansion. The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market. Consumers typically choose lower-cost generic erectile dysfunction pills over more expensive blockbuster kinds due to the profitable marketing of counterfeit erectile dysfunction drugs at considerably cheaper prices than either patented or generic pharmaceuticals. Aside from that, when patents on blockbuster pharmaceuticals expire, new generic equivalents are entering the market, generally at inexpensive rates. Global Erectile Dysfunction Drugs Market : Segmentation The global erectile dysfunction market is categorized based on therapeutics and region. By therapeutics, the global erectile dysfunction market is bifurcated into Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators. Get More Insight before [email protected] : List of Key Players of Erectile Dysfunction Drugs Market : Eli Lilly & Co. Pfizer Dong-A Pharmaceutical Co. Ltd Bayer AG Meda Pharmaceuticals Vivus Inc. Apricus Biosciences. Key questions answered in this report: What are the growth rate forecast and market size for Erectile Dysfunction Drugs Market ? What are the key driving factors propelling the Erectile Dysfunction Drugs Market forward? What are the most important companies in the Erectile Dysfunction Drugs Market Industry? What segments does the Erectile Dysfunction Drugs Market cover? How can I receive a free copy of the Erectile Dysfunction Drugs Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments May 2020, Metuchen Pharmaceuticals, L.L.C., a privately owned biopharmaceutical aimed at defining, developing, gaining, and commercializing revolutionary therapeutics for male sexual health conditions, and Neurotrope, Inc. ("Neurotrope") officially revealed that the two firms have decided to enter into a concise merger agreement within which Metuchen and Neurotrope, Inc. will unite in an all-stock purchase arising in a newly formed partnership firm ("Petros"). Petros is anticipated to become a Nasdaq-listed corporation specializing in men's health. Regional Dominance: North America is projected to lead the global market over the forecast period. North America is likely to dominate the global erectile dysfunction drugs market. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. When the last of the baby boom cohorts reach 65, the number of older individuals is predicted to climb by roughly 18 million between 2020 and 2030. Because ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. The domination of these countries is due to the availability of numerous ED medicines by OTC and internet outlets. The National Institute of Diabetes and Digestive and Kidney Diseases stated roughly 30 million men in the United States suffer from ED. Furthermore, the United States has the greatest rate of self-reported ED. As a result, rising ED prevalence in the US is likely to fuel market growth throughout the projection period. Global Erectile Dysfunction Drugs Market is segmented as follows: Erectile Dysfunction Drugs Market : By Therapeutics Type Outlook (2022-2028) Existing drugs Tadalafil Sildenafil Citrate Vardenafil Udenafil Stendra/Spedra Lodenafil Carbonate Mirodenafil Pipeline drugs Apomorphine Alprostadil Topiglan Gene Therapy Melanocortin Activators Erectile Dysfunction Drugs Market : By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Press Release For Erectile Dysfunction Drugs Market : Browse Other Related Research Reports from Zion Market Research Medical Enzyme Technology Market - Global Industry Analysis : The global Medical Enzyme Technology market accrued earnings worth approximately 4.5(USD Billion) in 2020 and is predicted to gain revenue of about 6.7(USD Billion) by 2028, is set to record a CAGR of nearly 6.2% over the period from 2021 to 2028. Respiratory Virus Infection Drugs Market - Global Industry Analysis : The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028. Animal Drug Compounding Market - Global Industry Analysis : The global Animal Drug Compounding market accrued earnings worth approximately 1.21(USD Billion) in 2020 and is predicted to gain revenue of about 3.31(USD Billion) by 2028, is set to record a CAGR of nearly 6.5% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Pharmaceutical Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog : | Market Business Insights Logo: SOURCE Zion Market Research

JMC 杂志的最新一篇综述文章，归纳了近20年的2000个药物的命名背后的信息，揭示了药物的结构规律和趋势。 世界卫生组织 (WHO) 根据药物开发人员的要求，为化合物指定 国际非专利药名 （international nonproprietary names ，INN） ，也称为药物的通用名。INNs的命名结构是公开的，分析其变化规律，可以帮助我们了解药物研究和开发的趋势。 通用名 ，也称为药物的通用名。INNs的命名结构是公开的，分析其变化规律，可以帮助我们了解药物研究和开发的趋势。 在许多国家，同一种药物销售时有多个品牌名称，这些品牌名称因国家而异。虽然化学家可能认为国际纯化学和应用化学联合会（IUPAC）的名称代表唯一的标识符，但这些名称很复杂，几乎不可能为普通公众记住，而且容易出错。因此，需要一个简短易读的通用名来识别世界各地的同一种药物。 1953年，世卫组织的理事机构世界卫生大会通过了WHA3.11号决议，由世卫组织的一个专家委员会“负责国际非专利药名（INN）的选择和批准”，并建议各国药典采用这样的名称。这一决议诞生了国际非专利药名（INN）系统，用于药物识别。它也是开发非专利药仿制药市场的一个关键支柱，在大多数国家，INNs替代了品牌名称，从而使制造商与治疗效果脱钩。 其他机构也会发布行业内的命名规则，如个人护理产品委员会发布通用国际命名法化妆品成分（INCI）名称，美国国家标准协会（ANSI）发布化学品的通用名称，国际标准化组织（ISO）也有自己的命名系统。这样，一些分子会因不同的用途会被多个主体共同命名，虽然在大多数情况下这些名称是一致的，但情况并非总是如此。 国际非专利药名（INNs）是如何定义的？ INN专家组由来自世界各地的专家组成，由秘书处领导和协调。专家可能包括医药化学家、药理学家、生物化学家、分子生物学家和临床医生。为了保持各领域的一致性，委员会也有一些其他学者参加，如国家命名机构和药典的代表、IUPAC专家，解剖治疗化学分类系统（ATC）代码专家等。 请求INN的个人或公司可以提出一个遵守INN系统规则和惯例的名称，委员会可以接受或修改该名称。简而言之，INN的核心元素是词干，由一个或两个音节组成，通常位于药品名称的末尾。这种词干识别具有共同特征的药物，通常是作用机制，也可以是治疗用途或化学/结构特征。 例如，质子泵抑制剂：奥美拉唑，埃索美拉唑，泮托拉唑，雷贝拉唑（omeprazole, esomeprazole, pantoprazole, rabeprazole）都有共同的词干拉唑（prazole），用以识别“抗溃疡，苯并咪唑衍生物”。 如果INN专家组不承认药物是广泛类别的一部分，它们将被指定一个唯一的词干。如果其他具有这种新特性的分子将来会有一个INN请求，那么这些分子将得到相同的结果，委员会将把它作为一个官方的词干来推广。世卫组织出版“词干书”并定期更新，可以自由查阅。 在INNs中使用词干、前缀、中缀和后缀 不仅词干限定了一个药名，前缀（INNs开头的一个音节）、中缀（单词中间的一个音节），或后缀（INNs末尾的一个音节）都可以用来描述药名的特征，并给读者提供信息。例如，音节-gli-表示许多用于糖尿病的药物（例如格列本脲、卡格列嗪、西他列汀、沙罗格列他嗪、罗格列酮）；注意-glifozin、-gliptin、-glitazar和-glitazone都是识别不同药物类别的词干，前缀gli-表示抗高血糖药，这是磺胺衍生物。关于INN专家组自2000年以来最常用的词干，见下表1： 编号 alkaloids and organic bases 生物碱和有机碱 tyrosine kinase inhibitors 酪氨酸激酶抑制剂 enzyme inhibitors 酶抑制剂 antivirals (undefined group 抗病毒 antihyperglycaemics 抗高血糖药 ketones 酮 immunomodulators, both stimulant/suppressive and stimulant 免疫调节剂 serine/threonine kinase inhibitors 丝苏氨酸激酶抑制 phosphorus derivatives; various pharmacological categories belonging to “fos”, other than insecticides, anthelminthics, pesticides, etc 磷衍生物 phosphatidylinositol 3-kinase inhibitors, antineoplastics PI3K抑制剂，抗肿瘤药 antiallergic or anti-inflammatory, not acting as antihistaminics 抗过敏或抗炎，不起抗组胺作用 neurokinin (tachykinin) receptor antagonists 神经激肽（速激肽）受体拮抗剂 angiogenesis inhibitors 血管生成抑制剂 抗肿瘤药物；有丝分裂抑制剂，微管蛋白粘合剂 cyclin dependent kinase inhibitors cyclin依赖性激酶抑制剂 阿拉伯呋喃酰基衍生物；核苷抗病毒或抗肿瘤药物，阿糖胞苷或氮胞苷衍生物 内皮素受体阻滞剂 抗菌药物，萘啶酸衍生物 系统性抗真菌药物，咪康唑衍生物 prostaglandins 前列腺素 囊性纤维化跨膜调节器（CFTR）蛋白调节剂、校正剂和放大器 烟碱型乙酰胆碱受体部分激动剂 抗肿瘤药物，拓扑异构酶I抑制剂 analgesics 止痛药 鸟苷酸环化酶激活剂和刺激剂 腺苷A受体激动剂 poly-ADP-Ribose polymerase inhibitors PARP抑制剂 支气管扩张剂，苯乙胺衍生物 加压素受体拮抗剂 近20年来INNs药物化学分析 本文收集2000-2021将SCE (small chemical entities ，小分子化学实体)， small chemical entities  (small chemical entities ，小分子化学实体)， 并细分为两个大小相似的子集进行数据分析，其中2000年至2011年的 A期 由1038个SCE组成，2012年至2021年的 B期 由980个SCE组成： SCEs药物类别的发展趋势 酪氨酸激酶、细胞周期蛋白依赖性激酶、丝氨酸/苏氨酸激酶和磷脂酰肌醇3激酶抑制剂在过去10年中引起了开发人员的极大兴趣。自2011年以来，几乎20%的SCE属于这四类，其中酪氨酸激酶抑制剂占了大多数。而 37种丝氨酸/苏氨酸激酶抑制剂中，迄今没有一种得到批准 。 在肿瘤学领域，一些化疗类药物并没有完全过时（例如，-bulin，-abine），而另一些药物（-tecan）则完全不受欢迎。 糖尿病领域和一些药物靶点（如神经激肽受体、血管加压素受体和内皮素受体）的INN分配显著下降。 一个专门为一种罕见疾病（囊性纤维化）开发的药物类别在过去10年中引起了足够的兴趣，发行了12个名称（-caftor）。 图6 最常见词干的频率 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 元素组成 绝大多数化合物中都含有碳、氢、氧和氮（CHON）； CHON之后，氟取代氯和硫成为CHON之后最常见的元素，30%以上化合物中含氟； 碘只存在于19种化合物中，硼存在于14个分子中。含碘分子的批准率较低（11%），而含硼分子的批准率显著高基准（20%）。在14个含硼分子中，有9个在B期，表明这种元素的使用量在增加。虽然这些分子中大部分都存在硼酸（N=8），但四个分子含有五元硼杂环，两个含有六元硼杂环。 其余元素为铂（N=5）、硅（N=3）、铁（N=3）、钯（N=2）、锰（N=2）、铋（N=1）、tin（N=1）、砷（N=1），含有这些不常见元素的分子如图所示。 元素组成比较 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 官能团 最常见的基团是醚键（N=962），其次是酰胺、内酰胺（N=840，42%）、脂肪族胺（伯胺、仲胺和叔胺；N=797，39%）和芳香胺（N=633，31%）。 药物设计中通常避免使用酯键，由于其水解不稳定性，但10%的INN分子含有该官能团。 含硫官能团在这两个时期的SCE数量相同，但硫醚的使用减少，磺酰胺的使用略有增加，砜的使用急剧增加。 α，β-不饱和羰基在B期减少，α，β-不饱和酰胺在同一时期略有增加。 官能团变化趋势 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 羧酸和脂肪胺的用量都有小幅下降，我们研究酸性、碱性、中性、两性离子化合物的比例发现，中性47%；碱性27%；酸性19%；两性离子7%；随着时间的推移，中性SCE略有增加，从A期平均43%的中性药物上升到B期的51%。 中性、酸性、碱性和两性离子SCE的分布 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 环系统 从方法学的观点来看，所有的环和稠环都被保留，还有内环键和外环羰基、磺酰基、亚胺、亚砜基和硫羰基。 总体上，我们在A期和B期分别发现362和419个不同的环系统，其中A、B期分别有224和257个环系统仅用于单个SCE，表明化学新颖性正在增加。 大多数含氮芳香环系统更多地出现在周期B中：吡啶、苯并咪唑和吡嗪增加了一倍，嘧啶几乎增加了三倍；吲唑尽管数量很少，但随着时间的推移正经历着显著的增加。这可能主要归因于酪氨酸激酶抑制剂（-tinib）的出现，它们的药效团中通常含有腺嘌呤模拟骨架。 含氮的脂肪环，包括氮杂环丁烷、吡咯烷和吗啡以及哌啶和哌嗪也在增加，尽管程度较小；这些子结构都越来越频繁地被用作增强溶解度。 尽管1,2,4-三唑呈稳定趋势，但由于点击化学方法的出现及其在药物开发中的应用（A期N=3；B期N=12），1,2,3-三唑尽管不在前30名之列，但仍在显著增加。 环系统变化 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 蓝色 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 橙色 A期（蓝色；2000-2011年：N=1038）和B期（橙色；2012-2021年：N=980） 对称化合物 大量的对称化合物令人印象深刻（N=29），在过去的20年里，这些分子的数量翻了一番，从2000年到2011年的10个增加到了过去10年的19个。 两种化合物实际上是前药，含有一个失活部分和两个相同的活性成分分子（碳酸洛地那非、癸二酸二丁啡）。 大多数其他对称化合物是设计用于靶向二聚体结构的蛋白质的传统双药。化学诱导二聚体（CID）技术导致rimiducid的出现。 代表性对称化合物的结构 分子复杂性 人们通常认为，由于药物靶标的挑战和合成可及性，药物分子正变得越来越复杂。 分子量：更大、更复杂的分子能够进入更大的化学空间，能够更好地调控靶蛋白三维结合位点。B期药物的MW比A期药物的MW高出10%。尽管MW正在增加，MW低于300的类药分子仍然具有较多的成药机会，2011-2016年间17%的药物MW小于300。我们也发现大量化合物的MW低于150，其中五种是世界范围内批准的新药。虽然MW500被认为是类药物化合物的阈值，但29%的INN化合物高于此限值，其中11.5%的INN为大环化合物（N=69）。 分子量低于150da的12个sce的结构 手性：在批准的药物中，64%的药物至少有一个立体中心，A/B期化合物数量相当。在同一时期，每个SCE的平均立体中心数则略有下降。8个SCE的立体中心数等于或大于20个，其中伊维尼米星的立体中心数最多为35个，其次是匹沙莫德有29个立体中心。 手性SCE的批准率为27%，略高于20%的平均值，在纯立体异构体（28%）和立体异构体混合物（26%）中没有差异。 螺环：得益于合成策略的最新进展，螺环被引入了更多分子结构。虽然环丙烷在药物研发中已应用多年，但环丁烷、氮杂环丁烷和氧杂环丁烷直到最近才流行起来。Bauer等人总结，环丙烷是最常用的小环，其次是环丁烷、氮杂环丁烷和氧杂环丁烷。尽管数量很少，但除了氧杂环丁烷外，所有环的使用随时间而增加，环丙烷的增长最为显著。有趣的是，环丁烷在2000-2007年期间没有出现，2008年开始出现，此后出现了15次。 含有螺环和小环的代表性药物 本文分析了2000年至2021年间的药物命名规律，发现一些化学结构的变化，如氟和杂环化合物的使用显著增加，分子量的逐渐增加，螺旋环支架和小环的增加，非传统结构的出现等，这些有可能预示药物的未来趋势。 虽然INNs数据库非常有助于审查正在开发的药物，并告知药物化学的趋势，但它不太可能永远赋予一个分子的成功特征，因为太多的变量及人的能动性会改变药物的未来样子。